Sandoz launches Letrozole, the generic version of Novartis’ Femara®
Frimley, UK, July 25, 2011
Sandoz Ltd. today announced the UK launch of Sandoz Letrozole, the generic version of Novartis’ Femara®, a drug used in the treatment of breast cancer.
According to IMS, UK branded sales of Letrozole amounted to GBP 39.4 million in 2010.
“This launch reflects our commitment to increasing patient access to affordable and high-quality medicines such as oncology medicines” said Pascal Brenneisen, Country Manager of Sandoz UK. “It is also an example of how Sandoz UK is helping to provide cost-savings to the NHS.”
Sandoz Letrozole will now be available from most major pharmaceutical wholesalers in the UK.
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as “launches,” “launch,” “introduction,” “commitment,” “anticipate,” or similar expressions, or by express or implied discussions regarding potential future approvals of additional oral contraceptive products, or regarding potential future revenues from Letrozole or such other products. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any additional oral contraceptive products will be submitted or approved by Sandoz for sale. Nor can there be any guarantee that Letrozole or any such other products will achieve any particular levels of revenue in the future. In particular, management’s expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including potential FDA approval of additional versions of Letrozole; unexpected product development difficulties; competition in general; government, industry and general public pricing pressures; unexpected patent litigation outcomes; the impact that the foregoing factors could have on the values attributed to the Novartis Group’s assets and liabilities as recorded in the Group’s consolidated balance sheet, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sandoz
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by valid and enforceable third-party patents. Sandoz has a portfolio of approximately 1000 compounds and sells its products in about 130 countries. Key product groups include cardiovascular medicines, anti-infectives, treatments for central nervous system and alimentary tract disorders, oncology and respiratory therapies, as well as medications for blood and blood forming organ disorders. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), and Oriel Therapeutics (US). In 2010, Sandoz employed more than 23,000 people (full-time equivalents) worldwide and achieved net sales of USD 8.5 billion for the full year.
# # #
For further information
Marija Mandic
Head, Global Media Relations
marija.mandic@sandoz.com
+49 8024 476 2597
